Artelo Biosciences, Inc.
ARTL
$7.16
-$0.15-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.36% | 41.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.81% | -1.94% | |||
| Operating Income | 9.81% | 1.94% | |||
| Income Before Tax | -33.53% | 3.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -33.53% | 3.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.53% | 3.14% | |||
| EBIT | 9.81% | 1.94% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 48.03% | 29.35% | |||
| Normalized Basic EPS | 62.20% | 29.35% | |||
| EPS Diluted | 48.03% | 29.35% | |||
| Normalized Diluted EPS | 62.20% | 29.35% | |||
| Average Basic Shares Outstanding | 156.93% | 37.11% | |||
| Average Diluted Shares Outstanding | 156.93% | 37.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||